Abstract #1321492: First Interim Analysis of Fibroblast Growth Factor 23–Related Hypophosphatemic Rickets and Osteomalacia Registry in the Gulf Region: Baseline Characteristics for Adult and Pediatric Population

Dubayee, Mohammed Al; Ahmad, Naveed; Aidarous, Salwa Al; Jubeh, Jamal Al; Juraibah, Fahad Al; Saffar, Hussain Al; Yaarubi, Saif Al; Al-Fares, Abdulah; Alkandari, Hessa; Alsagheir, Afaf; Alsubaihin, Abdul; Attia, Najya; Deeb, Asma; Fouda, Mona A.; Habeb, Abdelhadi

doi:10.1016/j.eprac.2022.10.108

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinicians and researchers from different countries also presented several e-posters. Therefore, the conference highlights will shed the light on the following main aspects: (1) etiology and genes, (2) treatment and impact, and (3) ongoing management, aiming to contribute to reducing the already recognized gaps in the treatment modalities/treatment pathway, treatment outcomes, mortality, and health care resource utilization in the Middle East, 2 especially with the increased number of diagnosed cases from the region 3 and the desire to raise the awareness on the recognition and modern management of X-linked hypophosphatemia (XLH). 4…”

Section: Introductionmentioning

confidence: 99%

X-Linked Hypophosphatemia at the European Society of Pediatric Endocrinology Meeting 2022

Alsaffar

Dauleh

Ali

2023

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Rickets, a growth plate disorder, is classified into calcipenic and phosphopenic types based on the etiology. Phosphopenic rickets can be further classified into fibroblast growth factor 23 (FGF23) mediated and non-FGF23 mediated. FGF-23 has a phosphaturic effect which results in hypophosphatemia and, therefore, the accumulation of hypertrophied chondrocytes, leading to rachitic changes in the bones. One of the most common causes of inherited hypophosphatemic rickets is X-linked hypophosphatemia (XLH), mainly due to a mutation in the PHEX gene that ends in the extended release of FGF-23. During the 60th annual meeting of the European Society for Pediatric Endocrinology, held in Rome between September 15 and 19, 2022, approximately 15 presentations were made either as free communication or poster. In addition, there was a dedicated satellite symposium focusing on XLH. This article has been prepared mainly to share knowledge and updates discussed during the meeting about hypophosphatemic rickets, as we feel this disease is still to be focused on in the MENA region, since there are some gaps in the recognition and management of FGF23 hypophosphatemic rickets and osteomalacia.

show abstract

Section: Introductionmentioning

confidence: 99%